Donald W Kufe

41PUBLICATIONS
72CO-AUTHORS
Molecular targetsTe urupare me te whai wāhi Māori ki te mātauranga (Māori responsiveness and engaged education)Predictive and prognostic markersCancer cell biologyCancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (41)

|Aug 05, 2026
M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitors.

|Jul 28, 2026
Evolution of MUC1 During Retrotransposon Expansion as a Potential Adaptation Exploited in Human Cancer.

|Jul 08, 2026
M1C IS NECESSARY FOR DARAXONRASIB RESISTANCE OF NSCLC KRAS(G12C) MUTANT CELLS.

|Nov 27, 2025
MUCIN 1 confers inflammatory memory of tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Shinkichi Takamori, Naoki Haratake, Atrayee Bhattacharya

|Oct 14, 2025
Targeting KRAS Inhibitor-Resistant Pancreatic Cancer with an MUC1-C Antibody-Drug Conjugate.

Hiroki Ozawa, Kazuki Takahashi, Tomoki Motegi

|Aug 08, 2025
Activation of APOBEC3 cytidine deaminases and endogenous retroviruses is integrated by MUC1-C in NSCLC cells.

Naoki Haratake, Shinkichi Takamori, Hideko Isozaki

Pageof 7

Frequent Collaborators

15 joint publications

Mark D Long

7 joint publications

Hiroki Ozawa

6 joint publications

Qiang Hu

5 joint publications

Kwok-Kin Wong